# Option Care Health account plan

> Option Care Health, the largest independent US home infusion provider, had FY2025 revenue of $5,649.5 million and is being acquired by CD&R and McKesson.

## At a glance

Option Care Health, headquartered in Bannockburn, Illinois, provides home and alternate site infusion services across the US: it supplies drugs and complex compounded solutions for intravenous delivery in patients' homes, infusion suites and clinics, with nursing, monitoring and reimbursement support. It contracts with managed care organizations and other payers, hospitals and health systems, physicians and pharmaceutical manufacturers. FY2025 net revenue was $5,649.5 million (+13.0%) and net income $207.6 million; at December 31, 2025 it had 6,528 full-time and 1,738 part-time employees, including more than 5,000 clinicians. Listed on Nasdaq (OPCH), it agreed on October 5, 2026 to be taken private by affiliates of Clayton, Dubilier & Rice and McKesson for $32.05 per share in cash, with closing expected in the first half of 2027.

## Business units

- **Infusion services** (about 98% of 2025 net revenue ($5,555.8 million)): The single reportable segment: clinical management of infusion therapy, nursing and care coordination through 87 full-service pharmacies and 188 ambulatory infusion suites. Therapies include anti-infectives, nutrition support, immunoglobulin, chronic inflammatory disorders, neurological and bleeding disorders, women's health and heart failure; acute revenue grew in the mid-teens and chronic in the low double digits in 2025.
- **Naven Health**: A nationwide home infusion nursing network and clinical platform focused on highly specialized infusion care.
- **Other revenue** ($93.7 million in 2025): Miscellaneous revenue streams, including management fees from two infusion joint ventures with health systems ($7.5 million in 2025).

## Strategic priorities

- **Grow site-of-care programs with payers**: Option Care has active site-of-care programs with the largest national payers and added five new programs with regional health plans and two with nontraditional payers in 2025, as payers look to lower costs.
- **Expand rare and orphan therapy platforms**: It runs over 20 platforms for rare or limited distribution drugs, with two more starting in 2026; growth vectors named are neurology, autoimmune, dermatology, oncology and rare diseases.
- **Build out infusion clinics**: Over 80 infusion chairs were added in 2025 and five new ambulatory infusion clinics opened in Q2 2026; over 35% of nursing visits now take place in a suite or clinic.
- **Automation and AI in operations**: About 40% of claims are processed without human intervention, and AI is deployed for nurse route and scheduling optimization, delivery routing, patient onboarding and claims.
- **Commercial reset**: Sales resources were realigned on top specialty practices and accounts to expand reach and frequency, with commercial hires from late 2025 expected to gain productivity in the second half of 2026.

## Latest results

In Q3 2026 (quarter to September 30, 2026) net revenue was $1,493.5 million, up 4.1%, gross margin 19.1% and net income $57.4 million, up 10.8%. Acute therapies grew high single digits, while chronic grew low single digits as IG/neuro and rare and orphan growth offset a decline in the chronic inflammatory disease (CID) portfolio. Over nine months revenue was $4,286.6 million (+2.5%) and operating cash flow rose to $286.2 million on lower inventory. CID dynamics are still expected to cut 2026 gross profit by about $55 million, and the company withdrew its 2026 guidance when it agreed to the take-private deal.

## Investments and deals

- **Take-private by CD&R and McKesson**: Agreed on October 5, 2026 at $32.05 per share, an enterprise value of about $5.8 billion; CD&R will hold about 51% and McKesson will invest about $1.4 billion for about 49%, with a framework for McKesson to later buy CD&R's interest.
- **Intramed Plus acquisition**: Acquired on January 24, 2025 for $117.2 million net of cash; its South Carolina site grew volumes 25% year over year.
- **Share repurchases**: $310.0 million repurchased in 2025 and $167.5 million in the first nine months of 2026, with the authorization raised to $1 billion; buybacks are now frozen by the merger agreement.
- **Refinancing**: The term loan was refinanced in September 2025 at Term SOFR + 1.75% to 2032, and the revolver now provides up to $850.0 million.

## Challenges and risks

- **CID and biosimilar headwind**: Stelara biosimilar conversion and CID patient attrition are expected to cut 2026 gross profit by about $55 million, and higher-cost chronic therapies dilute gross margin, which fell to 19.3% in 2025 from 20.3%.
- **Restrictions while the merger is pending**: Acquisitions, capex, financing, pay increases and buybacks need the buyer's consent until closing, which may limit or delay strategic investments.
- **Payer dependence and rate pressure**: The largest payer is about 14% of revenue; payer bidding and consolidation, pricing benchmarks and rate pressure for Medicare Advantage exposure are named risks.
- **Clinician shortages**: Shortages of nurses and pharmacists are a named risk for a business that relies on a nursing team of about 2,700.
- **Supplier concentration**: About 55% of Q3 2026 drug and supply purchases came from three vendors.

## What leadership says

> "continue investing strategically and accelerate the pace of our advanced technology deployment to improve clinical outcomes and reduce the total cost of care" — John C. Rademacher, President and CEO, CD&R and McKesson acquisition press release, October 6, 2026

> "Although I am pleased with our progress in the second quarter, I am not satisfied with our performance." — John C. Rademacher, President and CEO, Q2 2026 earnings call, July 29, 2026

> "we believe the application of artificial intelligence will reduce the cost of healthcare while improving clinician efficiency" — John C. Rademacher, President and CEO, Q2 2026 earnings call, July 29, 2026

> "provides immediate cash value for our stockholders" — Harry Kraemer, Chairman, CD&R and McKesson acquisition press release, October 6, 2026


## Where a supplier can help

- **Technology to accelerate deployment**: Tied to the automation and AI priority and the CEO's aim to accelerate advanced technology deployment under new owners: claims automation, scheduling, routing and patient onboarding tools.
- **Clinician recruiting and retention**: Tied to the clinician-shortage challenge and the clinic build-out: nurse and pharmacist staffing, scheduling and retention solutions.
- **Pharma commercialization services**: Tied to the rare and orphan platform priority: data, clinical trial support and patient-program services for manufacturers launching limited distribution drugs.
- **Infusion clinic fit-out**: Tied to the clinic build-out: chairs, equipment and site services for new and converted infusion suites, timed around capex limits while the merger is pending.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Annual Report on Form 10-K for the year ended December 31, 2025](https://www.sec.gov/Archives/edgar/data/1014739/000101473926000008/bios-20251231.htm)

Annual report · 2026-02-24

- Option Care Health is the largest independent provider of home and alternate site infusion services in the U.S., with a national network of 196 locations in 43 states (87 full-service pharmacies, 73 of them with ambulatory infusion suites, plus 109 stand-alone ambulatory infusion suites, 27 with advanced practitioner capabilities) and more than 5,000 clinicians.
- FY2025 net revenue was $5,649.5 million, up 13.0% from $4,998.2 million; gross profit rose 7.4% to $1,087.9 million but gross margin fell to 19.3% from 20.3%; operating income was $337.9 million and net income $207.6 million (down 2.0%).
- Growth was organic: acute revenue grew in the mid-teens (helped by shifts in the competitive landscape) and chronic revenue in the low double digits; margin dilution came from higher-cost chronic therapies (rare and orphan) and biosimilar adoption, which management expects to cut gross profit by $25 million to $35 million in 2026.
- One reportable segment, infusion services ($5,555.8 million of revenue in 2025); by payer, commercial payers brought $4,902.4 million, government payers $681.6 million and patients $65.5 million. The largest payer was about 14% of revenue; direct government programs about 12%.
- Customers and partners: managed care organizations and other payers, hospitals and health systems (two infusion joint ventures with health systems), physicians and specialty prescribers, and pharmaceutical manufacturers that use it as a distribution channel for new launches; about 68% of drug and supply purchases came from four vendors.
- Capital deployment: Intramed Plus acquired on January 24, 2025 for $117.2 million net of cash; $310.0 million of share repurchases in 2025, and the buyback authorization was raised from $500 million to $1 billion in January 2026; term loan refinanced in September 2025 at Term SOFR + 1.75%, maturing 2032.
- Workforce at December 31, 2025: 6,528 full-time and 1,738 part-time employees, including a nursing team of about 2,700; competitors named include Optum Infusion Pharmacy, Coram CVS/specialty infusion services, Amerita (BrightSpring), KabaFusion, Soleo Health and Vital Care.
- Main risks: dependence on payers and their bidding and consolidation, drug pricing benchmarks (AWP/ASP), new lower-margin drugs and biosimilars, nursing and pharmacist shortages, government reimbursement, compounding regulation, cybersecurity and AI governance.

### [Quarterly Report on Form 10-Q for the quarter ended September 30, 2026](https://www.sec.gov/Archives/edgar/data/1014739/000101473926000029/bios-20260930.htm)

Interim report · 2026-11-04

- Q3 2026 (quarter to September 30, 2026): net revenue $1,493.5 million, up 4.1%; gross profit $285.0 million (19.1% margin); operating income $89.2 million; net income $57.4 million, up 10.8%.
- Nine months 2026: revenue $4,286.6 million, up 2.5%; gross margin 19.0% vs 19.2%; net income $156.7 million, up 5.1%; operating cash flow $286.2 million vs $222.6 million, helped by lower inventory.
- Acute therapies grew high single digits in Q3; chronic grew low single digits, with growth in IG/neuro and rare and orphan offset by a decline in the chronic inflammatory disease (CID) portfolio; CID dynamics are still expected to cut 2026 gross profit by about $55 million.
- Pending take-private: on October 5, 2026 the company agreed to be acquired by affiliates of Clayton, Dubilier & Rice and McKesson for $32.05 per share in cash; closing expected in the first half of 2027, after which the stock will be delisted.
- While the merger is pending, acquisitions, capex, financing, hiring pay and buybacks are restricted without the buyer's consent; Q3 SG&A rose 3.2% mainly on merger transaction costs.
- Network now 87 full-service pharmacies and 188 ambulatory infusion suites, 33 with advanced practitioner capabilities; revolver raised to $850 million (net availability $846.0 million); cash $299.1 million.
- 7,880,038 shares were bought back in the first nine months for $167.5 million (none in Q3); the largest payer stays at about 14% of revenue and direct government programs at about 13%.

### [CD&R and McKesson Corporation Sign Agreement to Acquire Option Care Health (press release, 8-K exhibit 99.1)](https://www.sec.gov/Archives/edgar/data/1014739/000110465926113904/tm2627097d1_ex99-1.htm)

Report · 2026-10-06

- On October 6, 2026, CD&R and McKesson announced an agreement to acquire Option Care Health for $32.05 per share in cash, an enterprise value of about $5.8 billion and a premium of about 37% to the October 5 close.
- CD&R will hold about 51% and McKesson will invest about $1.4 billion for about 49%; the deal sets up a framework for McKesson to later buy CD&R's interest, subject to conditions and approvals.
- Option Care Health will remain a separate company led by its own management team and "will continue to operate as usual".
- CEO John C. Rademacher said the backing would let the company "continue investing strategically and accelerate the pace of our advanced technology deployment".
- McKesson's CEO Brian Tyler framed it as part of a strategy to expand access to innovative therapies in lower-cost community settings, at or closer to home, and to bring McKesson's specialty pharmaceuticals expertise.
- Closing is expected in the first half of 2027, subject to stockholder and regulatory approvals; the company held no Q3 call and withdrew its 2026 guidance.
- The company presents itself as having over 8,000 team members, more than 5,000 clinicians, serving patients in all 50 states.

### [Option Care Health Q4 and full-year 2025 earnings call transcript](https://www.fool.com/earnings/call-transcripts/2026/02/24/option-care-opch-earnings-call-transcript/)

Executive talk · John C. Rademacher, President and Chief Executive Officer · 2026-02-24

- 2025 results call (February 24, 2026), CEO John Rademacher and CFO Meenal Sethna: net revenue $5.6 billion, up 13%; adjusted EBITDA $471 million, up 6% (8.3% margin); adjusted diluted EPS $1.72, up 9%; operating cash flow $258 million; net leverage 2.0x.
- Scale: over 315,000 unique patients and more than 2,500,000 infusion events in 2025; over 34% of nursing visits were in suites or clinics.
- Payers: active site-of-care programs with the largest national payers; five new programs with regional health plans and two with nontraditional payers (conveners, direct-to-employer) added in 2025.
- Pharma: over 20 rare or limited distribution drug platforms, with two more starting in 2026; growth vectors named as neurology, autoimmune, dermatology, oncology and rare diseases.
- Technology: about 40% of claims processed without human intervention; AI also used in call centers (agentic), workforce optimization and inventory, but not yet in the clinical pathway.
- 2026 guidance (since withdrawn): revenue $5.8-$6.0 billion with a 400 bp Stelara headwind, adjusted EBITDA $480-$500 million, adjusted EPS $1.82-$1.92, operating cash flow at least $340 million; capex $40-$50 million.
- Capital allocation: organic investment first, then tuck-in M&A ("IntraMed-like assets"), then periodic buybacks; over $300 million repurchased in 2025.
- On the market: infused products are "over $100 billion" and Option Care is "$6 billion of that"; Rademacher calls it "a hustle business".

### [Option Care Health Q2 2026 earnings call transcript](https://www.webull.com/news/15364520789042176)

Executive talk · John C. Rademacher, President and Chief Executive Officer · 2026-07-29

- Q2 2026 earnings call, CEO John Rademacher and CFO Meenal Sethna, the last call before the take-private deal: revenue $1.4 billion, up 2% year over year and 7% sequentially; adjusted EBITDA $117.5 million, up 3%; adjusted EPS $0.45.
- Acute posted high single-digit organic growth again; chronic was flat year over year but up high single digits sequentially; IG/neuro and rare and orphan grew; CID census stabilized after the Q1 "reset".
- The CID/Stelara headwind was still put at about 600 bp of revenue and $55 million of gross profit for 2026.
- Guidance then: revenue $5.675-$5.775 billion, adjusted EBITDA $480-$495 million, adjusted EPS $1.85-$1.92, operating cash flow at least $320 million (later withdrawn).
- Commercial reset: sales resources realigned on top specialty practices and accounts for "reach and frequency"; new rare and orphan therapies added, some going live late 2026 or early 2027.
- Technology: AI for nurse route and scheduling optimization, delivery routing, patient admission and onboarding, claims and patient communication; operating cash flow was $184 million in the quarter.
- Five new infusion clinics opened in the quarter; clinic visits grew more than 20%, and over 35% of nursing visits happened in suites or clinics.
- Rademacher: "I am not satisfied with our performance", knowing "we have much greater potential"; white-bagging has had no significant impact because "We are a pharmacy".

## Questions about Option Care Health

### What does Option Care Health do?

It provides home and alternate site infusion services, supplying drugs and compounded solutions for intravenous delivery in homes, infusion suites and clinics, with nursing and reimbursement support.

### What is Option Care Health's revenue?

FY2025 net revenue was $5,649.5 million, up 13.0%; Q3 2026 net revenue was $1,493.5 million, up 4.1%.

### How many employees does Option Care Health have?

At December 31, 2025 it had 6,528 full-time and 1,738 part-time employees, including more than 5,000 clinicians.

### Who is acquiring Option Care Health?

Affiliates of Clayton, Dubilier & Rice and McKesson agreed on October 5, 2026 to acquire it for $32.05 per share in cash, with closing expected in the first half of 2027.

### Who leads Option Care Health?

John C. Rademacher is President and CEO, Meenal Sethna is CFO, and Harry M. Jansen Kraemer, Jr. is Non-Executive Chairman.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
